Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 4/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 5/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.32 |
| ▸ | GSK3A | P49840 | 1/20 | 0.31 |
| ▸ | GSK3B | P49841 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31152368 | 1.00 | CYP2C19 (0.33) | CYP2C19CYP3A4CYP2C9BRD4GSK3A | |
| SCHEMBL12573129 | 0.84 | JAK2 (0.43) | CYP2C19CYP3A4CYP2C9 | |
| SCHEMBL31152357 | 0.84 | JAK2 (0.43) | CYP2C19CYP3A4CYP2C9 | |
| SCHEMBL18270927 | 0.84 | AURKA (0.43) | GSK3AGSK3B | |
| SCHEMBL14685262 | 0.84 | GSK3A (0.38) | CYP3A4CYP2C9GSK3AGSK3B | |
| SCHEMBL5138075 | 0.78 | RPS6KA5 (0.37) | — | |
| SCHEMBL22883506 | 0.77 | PDK2 (0.36) | — | |
| SCHEMBL21961971 | 0.76 | MAPK1 (0.42) | — | |
| SCHEMBL12572870 | 0.76 | KIT (0.50) | GSK3B | |
| SCHEMBL20315297 | 0.75 | MAPK1 (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4692089-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AS AAK1 INHIBITOR | Alicorn Pharmaceutical Co., Ltd. (CN) | 2026-02-11 | — | — | EP | disclosed |
| WO-2024207945-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AS AAK1 INHIBITOR | 艾立康药业股份有限公司 | 2024-10-10 | — | — | WO | disclosed |
| US-20180155342-A1 | INHIBITORS OF INFLUENZA VIRUSES REPLICATION | VERTEX PHARMACEUTICALS INCORPORATED | 2018-06-07 | — | — | US | disclosed |
| US-9908878-B2 | Inhibitors of influenza viruses replication | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2018-03-06 | — | — | US | disclosed |
| EP-3141252-A1 | INHIBITORS OF INFLUENZA VIRUSES REPLICATION | Vertex Pharmaceuticals Inc. (US) | 2017-03-15 | — | — | EP | disclosed |
| US-20160355512-A1 | INHIBITORS OF INFLUENZA VIRUSES REPLICATION | VERTEX PHARMACEUTICALS INCORPORATED | 2016-12-08 | — | — | US | disclosed |
| US-9394302-B2 | Inhibitors of influenza viruses replication | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2016-07-19 | — | — | US | disclosed |
| US-20150191468-A1 | INHIBITORS OF INFLUENZA VIRUSES REPLICATION | VERTEX PHARMACEUTICALS INCORPORATED | 2015-07-09 | — | — | US | disclosed |
| US-9051319-B2 | Inhibitors of influenza viruses replication | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160355512-A1 | INHIBITORS OF INFLUENZA VIRUSES REPLICATION | ACE, RNASEH1, ACE2 | CYP2C19 565/4885CYP3A4 2372/4885CYP2C9 1587/4885 |
| US-20150191468-A1 | INHIBITORS OF INFLUENZA VIRUSES REPLICATION | ACE, RNASEH1, ACE2 | CYP2C19 565/4885CYP3A4 2372/4885CYP2C9 1587/4885 |
| US-20180155342-A1 | INHIBITORS OF INFLUENZA VIRUSES REPLICATION | ACE, RNASEH1, ACE2 | CYP2C19 565/4885CYP3A4 2372/4885CYP2C9 1587/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.